Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 1053-1062

  Han, Xuezhe ^a   Yoon, Sung Hoon ^b   Ding, Yan ^b   Choi, Tae Gyu ^b   Choi, Won Joon ^c   Kim, Yun Hong ^c   Kim, Young Joo ^d   Huh, Young Buhm ^b   Ha, Joohun ^b   Kim, Sung Soo ^b  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b Kyung Hee University Hospital   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Jeju National University School of Medicine   (South Korea)

Author keywords

Cyclophilin A; Cylcosporin A; Glioma; Peptidyl prolyl cis trans isomerase activity; Sanglifehrin A

Indexed keywords

CISPLATIN; CYCLOSPORIN A; GLUTATHIONE; PEPTIDYLPROLYL ISOMERASE; SANGLIFEHRIN A; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; GLIOBLASTOMA; GLIOMA CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLOPHILIN A; CYCLOSPORINE; DRUG SYNERGISM; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; LACTONES; RATS; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SPIRO COMPOUNDS;

EID: 77949471266     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000732     Document Type: Article

References (48)

1. Counsell CE and Grant R: Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results. J Neurooncol 37: 241-250, 1998.
2. Pobereskin LH and Chadduck JB: Incidence of brain tumours in two English counties: a population based study. J Neurol Neurosurg Psychiatry 69: 464-471, 2000.
3. Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY: Primary brain tumours in adults. Lancet 361: 323-331, 2003.
4. Bredel M: Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35: 161-204, 2001.
5. Handschumacher RE, Harding MW, Rice J, Drugge RJ and Speicher DW: Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226: 544-547, 1984.
6. Li M, Wang H, Li F, Fisher WE, Chen C and Yao Q: Effect of cyclophilin A on gene expression in human pancreatic cancer cells. Am J Surg 190: 739-745, 2005.
7. Shen J, Person MD, Zhu J, Abbruzzese JL and Li D: Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res 64: 9018-9026, 2004.
8. Fillies T, Werkmeister R, van Diest PJ, et al: HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 5: 84, 2004.
9. Rey O, Baluda MA and Park NH: Differential gene expression in neoplastic and human papillomavirus-immortalized oral keratinocytes. Oncogene 18: 827-831, 1999.
10. Howard BA, Furumai R, Campa MJ, et al: Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small cell lung tumor growth in vivo. Cancer Res 65: 8853-8860, 2005.
11. Howard BA, Zheng Z, Campa MJ, et al: Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. Lung Cancer 46: 313-323, 2004.
12. Seko Y, Fujimura T, Taka H, et al: Hypoxia followed by reoxygenation induces secretion of cyclophilin A from cultured rat cardiac myocytes. Biochem Biophys Res Commun 317: 162-168, 2004.
13. Doyle V, Virji S and Crompton M: Evidence that cyclophilin-A protects cells against oxidative stress. Biochem J 341: 127-132, 1999.
14. Hong F, Lee J, Song JW, et al: Cyclosporin A blocks muscle differentiation by inducing oxidative stress and inhibiting the peptidyl-prolyl-cis-trans isomerase activity of cyclophilin A: cyclophilin A protects myoblasts from cyclosporin A-induced cytotoxicity. FASEB J 16: 1633-1635, 2002.
15. Choi KJ, Piao YJ, Lim MJ, et al: Overexpressed cyclophilin A in cancer cells renders resistance to hypoxia- and cisplatininduced cell death. Cancer Res 67: 3654-3662, 2007.
16. Fehr T, Kallen J, Oberer L, Sanglier JJ and Schilling W: Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties. J Antibiot (Tokyo) 52: 474-479, 1999.
17. Ivery MT: Immunophilins: switched on protein binding domains? Med Res Rev 20: 452-484, 2000.
18. Ho IC, Kim JH, Rooney JW, Spiegelman BM and Glimcher LH: A potential role for the nuclear factor of activated T cells family of transcriptional regulatory proteins in adipogenesis. Proc Natl Acad Sci USA 95: 15537-15541, 1998.
19. Musaro A, McCullagh KJ, Naya FJ, Olson EN and Rosenthal N: IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1. Nature 400: 581-585, 1999.
20. 2+-dependent calcineurin signalling pathway. Nature 400: 576-581, 1999.
21. Pyrzynska B, Serrano M, Martinez A and Kaminska B: Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A. J Biol Chem 277: 14102-14108, 2002.
22. Jordan P and Carmo-Fonseca M: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57: 1229-1235, 2000.
23. Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43, 2001.
24. Rajesh D, Stenzel RA and Howard SP: Perillyl alcohol as a radio-/chemosensitizer in malignant glioma. J Biol Chem 278: 35968-35978, 2003.
25. Ross SA, Carr CA, Briet JW and Lowe G.: Transfer of 4'-chloro-2,2':6', 2''-terpyridine platinum(II) between human serum albumin, glutathione and other thiolate ligands. A possible selective natural transport mechanism for the delivery of platinum(II) drugs to tumour cells. Anticancer Drug Des 15: 431-439, 2000.
26. Lowe G, Droz AS, Vilaivan T, et al: Cytotoxicity of (2,2':6',2''-terpyridine)platinum(II) complexes to Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei. J Med Chem 42: 999-1006, 1999.
27. Ahmadi R, Urig S, Hartmann M, et al: Antiglioma activity of 2,2':6',2''-terpyridineplatinum(II) complexes in a rat model-effects on cellular redox metabolism. Free Radic Biol Med 40: 763-778, 2006.
28. Huang PH, Mukasa A, Bonavia R, et al: Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104: 12867-12872, 2007.
29. Nakahara C, Nakamura K, Yamanaka N, et al: Cyclosporin-A enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in human gastric carcinoma cells. Clin Cancer Res 9: 5409-5416, 2003.
30. Ding Y, Choi KJ, Kim JH, et al: Endogenous hydrogen peroxide regulates glutathione redox via nuclear factor erythroid 2-related factor 2 downstream of phosphatidylinositol 3-kinase during muscle differentiation. Am J Pathol 172: 1529-1541, 2008.
31. Lee SM, Han X, Choi KJ, et al: A new method for purification of functional recombinant GST-cyclophilin A protein from E. coli. Indian J Biochem Biophys 45: 374-378, 2008.
32. Zhang LH, Youn HD and Liu JO: Inhibition of cell cycle progression by the novel cyclophilin ligand sanglifehrin A is mediated through the NFkappa B-dependent activation of p53. J Biol Chem 276: 43534-43540, 2001.
33. Orth K, Chinnaiyan AM, Garg M, Froelich CJ and Dixit VM: The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 271: 16443-16446, 1996.
34. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 326: 1-16, 1997.
35. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
36. Jeon SH, Piao YJ, Choi KJ, et al: Prednisolone suppresses cyclosporin A-induced apoptosis but not cell cycle arrest in MDCK cells. Arch Biochem Biophys 435: 382-392, 2005.
37. Clarke SJ, McStay GP and Halestrap AP: Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J Biol Chem 277: 34793-34799, 2002.
38. Lee CG, Heijn M, Di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60: 5565-5570, 2000
39. Bassan R, Lerede T, Borleri G, et al: Phase I trial with escalating doses of idarubicin and multidrug resistance reversal by shortcourse cyclosporin A, sequential high-dose cytosine arabinoside, and granulocyte colony-stimulating factor for adult patients with refractory acute leukemia. Haematologica 87: 257-263, 2002.
40. Hirsch-Ernst KI, Ziemann C, Rustenbeck I and Kahl GF: Inhibitors of mdr1-dependent transport activity delay accumulation of the mdr1 substrate rhodamine 123 in primary rat hepatocyte cultures. Toxicology 167: 47-57, 2001.
41. Lum BL, Kaubisch S, Fisher GA, Brown BW and Sikic BI: Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. Cancer Chemother Pharmacol 45: 305-311, 2000.
42. Sigal NH, Dumont F, Durette P, et al: Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med 173: 619-628, 1991.
43. Boulos S, Meloni BP, Arthur PG, et al: Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptormediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol Dis 25: 54-64, 2007.
44. Sameshima T, Nabeshima K, Toole BP, et al: Expression of emmprin (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas. Int J Cancer 88: 21-27, 2000.
45. Goldner FM and Patrick JW: Neuronal localization of the cyclophilin A protein in the adult rat brain. J Comp Neurol 372: 283-293, 1996.
46. Davies DC: Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 200: 639-646, 2002.
47. Frei UA, Neumayer HH, Buchholz B, Niese D and Mueller EA: Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Transplantation 65: 1455-1460, 1998.
48. Levy G, Burra P, Cavallari A, et al: Improved clinical outcomes for liver transplant recipients using cyclosporin monitoring based on 2-hr post-dose levels (C2). Transplantation 73: 953-959, 2002.